Literature DB >> 26109674

Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?

Dario Cocito1, Aristide Merola1, Alberto Romagnolo1, Erdita Peci1, Antonio Toscano2, Anna Mazzeo2, Luca Gentile2, Massimo Russo2, Raffaella Fazio3, Massimiliano Filosto4, Gabriele Siciliano5, Erica Schirinzi5, Eduardo Nobile-Orazio6, Leonardo Lopiano1.   

Abstract

Entities:  

Keywords:  EMG; MYELIN; NEUROPATHY; NEUROPHYSIOL, CLINICAL; PERIPHERAL NEUROPATHOLOGY

Mesh：

Substances：

Year:  2015        PMID： 26109674     DOI： 10.1136/jnnp-2014-310280

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  9 in total

Review 1.  Update on therapy of chronic immune-mediated neuropathies.

Authors:  Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

Review 2.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

Review 3.  Sustained response to subcutaneous immunoglobulins in chronic ataxic neuropathy with anti-disialosyl IgM antibodies (CANDA): report of two cases and review of the literature.

Authors:  D Marastoni; L Africa; G M Fabrizi; F Giannini; A Peretti; S Bocci; L Insana; S Ferrari; F Ginanneschi; G Zanette
Journal:  J Neurol       Date:  2020-04-28       Impact factor: 4.849

Review 4.  Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.

Authors:  Jeremy Chung Bo Chiang; Ria Arnold; Roshan Dhanapalaratnam; Maria Markoulli; Arun V Krishnan
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-15

5.  Retrospective correlation analysis of plasma Immunoglobulin G and clinical performance in CIDP.

Authors:  Lars Kjøbsted Markvardsen; Stine Bruun-Sørensen; Ingelise Christiansen; Henning Andersen
Journal:  PeerJ       Date:  2019-05-16       Impact factor: 2.984

6.  Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

Authors:  Ivo N van Schaik; Orell Mielke; Vera Bril; Nan van Geloven; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Michaela Praus; Billie L Durn; David R Cornblath; Ingemar S J Merkies
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-07-03

7.  Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy.

Authors:  Luca Gentile; Massimo Russo; Carmelo Rodolico; Ilenia Arimatea; Giuseppe Vita; Antonio Toscano; Anna Mazzeo
Journal:  Sci Rep       Date:  2021-04-28       Impact factor: 4.379

8.  Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.

Authors:  Ivo N van Schaik; Nan van Geloven; Vera Bril; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Orell Mielke; David R Cornblath; Ingemar S J Merkies
Journal:  Trials       Date:  2016-07-25       Impact factor: 2.279

Review 9.  Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic.

Authors:  Yusuf A Rajabally; H Stephan Goedee; Shahram Attarian; Hans-Peter Hartung
Journal:  Muscle Nerve       Date:  2020-04-24       Impact factor: 3.852
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.